The approval by the European Commission was based on results from the Phase 3 POLO trial, which were published in The New England Journal of Medicine.
It follows the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Pancreatic cancer is a rare, life-threatening disease with the lowest survival rate of the most common cancers. Approximately 5-7% of patients with metastatic pancreatic cancer have a germline BRCA mutation.
The POLO trial demonstrated that LYNPARZA nearly doubled the time patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months versus 3.8 months on placebo (HR 0.53 [95% CI 0.35-0.81] p=0.0035).
The safety and tolerability profile of LYNPARZA in the POLO trial was consistent with previous trials. The most common adverse reactions ≥10% were fatigue/asthenia, nausea, abdominal pain, diarrhea, anemia, decreased appetite, constipation, vomiting, back pain, arthralgia, rash, thrombocytopenia, dyspnea, neutropenia, nasopharyngitis, dysgeusia and stomatitis.
The most common ≥ Grade 3 ARs were anemia, fatigue/asthenia, decreased appetite, abdominal pain, vomiting and arthralgia. Among patients taking LYNPARZA, dose interruptions due to an AR of any grade occurred in 35% and dose reductions due to an AR occurred in 17%. Discontinuation due to ARs occurred in 6% of patients receiving LYNPARZA.
LYNPARZA is approved in the US and several other countries as a first-line maintenance treatment for patients with gBRCAm metastatic pancreatic cancer whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen, based on the Phase 3 POLO trial, with ongoing regulatory reviews in other jurisdictions.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT